

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Oder 1



Section 1. Identifying Inform	ation					
Given Name (First Name)  Daniel	2. Surname (Last Name) Oder	3. Date 10-November-2020				
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Peter Nordbeck				
5. Manuscript Title Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review						
6. Manuscript Identifying Number (if you kn	now it)	_				
Section 2						
Section 2. The Work Under Co	onsideration for Public	cation				
		a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,				
Are there any relevant conflicts of intere						
If yes, please fill out the appropriate info Excess rows can be removed by pressing		re more than one entity press the "ADD" button to add a row.				
Name of Institution/Company	Grant	n-Financial other? Comments				
Sanofi						
Takeda						
Section 3. Relevant financial	activities outside the s	submitted work.				
of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	bed in the instructions. Us port relationships that wer est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.				
If yes, please fill out the appropriate info	ormation below.					
Name of Entity	Grant	n-Financial other? Comments				
Sanofi						
Takeda						

Oder 2



Section 4. Intellectual Property Patents & Copyrights						
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo						
Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Statement						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Oder reports personal fees from Sanofi, personal fees from Takeda, during the conduct of the study; personal fees from Sanofi, personal fees from Takeda, outside the submitted work; .						

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Oder 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Cartian 1							
Section 1. Identifying Information							
1. Given Name (First Name) Jonas	2. Surname (Last Name) Müntze	3. Date 10-November-2020					
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Peter Nordbeck					
5. Manuscript Title Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review							
6. Manuscript Identifying Number (if you kno	ow it)	_					
Continue 2							
Section 2. The Work Under Co	onsideration for Public	ation					
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?   Yes   No  If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.							
Name of Institution/Company	Grant	n-Financial other? Comments					
Amicus							
dorsia							
Sanofi	<b>✓</b>						
Fakeda							
Section 3. Relevant financial a	activities outside the s	ubmitted work.					
of compensation) with entities as describ clicking the "Add +" box. You should rep	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.					
Are there any relevant conflicts of interest?							



Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Amicus			<b>✓</b>				
Idorsia			<b>✓</b>				
Sanofi		<b>✓</b>	<b>✓</b>				
Takeda			<b>✓</b>				
Section 4.	Intellectual Propert	ty Pate	ents & Cop	pyrights			
	patents, whether plann	ed, pendi	ing or issue	ed, broadly releva	int to the	work? Yes 🗸 No	
Section 5.	Relationships not c	overed	above				
	elationships or activities encing, what you wrote i				influence	d, or that give the appearance of	
Yes, the follow	wing relationships/conc	ditions/cir	cumstance	s are present (exp	plain belo	w):	
✓ No other rela	tionships/conditions/ci	rcumstand	ces that pre	esent a potential	conflict of	finterest	
	anuscript acceptance, jo rnals may ask authors to					sary, update their disclosure stater elationships.	ments.
Section 6.	Disclosure Stateme	nt					
Based on the abo	ove disclosures, this forn	n will auto	omatically (	generate a disclo	sure state	ment, which will appear in the bo	x
fees from Takeda		f the stud	y; persona	l fees from Amicu	ıs, person	ersonal fees from Sanofi, personal al fees from Idorsia, grants and	



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above. 5.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform	nation		
Given Name (First Name) Peter	2. Surname (Last Name) Nordbeck		3. Date 10-November-2020
4. Are you the corresponding author?	✓ Yes No		
5. Manuscript Title Contemporary therapeutics and new d	rug developments for tr	eatment of Fabry dis	ease: a narrative review
6. Manuscript Identifying Number (if you k CDT-20-743	now it)		
Section 2. The Work Under C	onsideration for Pub	lication	
any aspect of the submitted work (including statistical analysis, etc.)?	g but not limited to grants,		nment, commercial, private foundation, etc.) I, study design, manuscript preparation,
Are there any relevant conflicts of inter			intity proceeds "ADD" button to add a re-
Excess rows can be removed by pressir		iave more than one e	entity press the "ADD" button to add a ro
Name of Institution/Company	Grant? Personal Fees?	on-Financial Othe	r? Comments
micus	<b>✓</b>		
lorsia	<b>✓</b>		
anofi	<b>✓</b>		
akeda	<b>✓</b>		
Section 3. Relevant financial	activities outside th	e submitted work	
	ibed in the instructions. port relationships that w	Use one line for each vere <b>present during</b>	ancial relationships (regardless of amour n entity; add as many lines as you need b the 36 months prior to publication.



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Amicus	<b>✓</b>	<b>✓</b>				
Idorsia	<b>✓</b>	<b>√</b>				
Sanofi	<b>✓</b>	$\checkmark$				
Takeda	<b>✓</b>	$\checkmark$				
Section 4. Intellectual Propert  Do you have any patents, whether plann	•			nt to the	work? ☐ Yes 🗸 No	
Section 5. Relationships not c	overed	above				
Are there other relationships or activities potentially influencing, what you wrote i				nfluenced	d, or that give the appearance of	
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	w):	
✓ No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict of	interest	
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						nents.
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.	า will auto	omatically (	generate a disclos	sure state	ment, which will appear in the box	
Dr. Nordbeck reports grants and personal from Sanofi, grants and personal fees frogrants and personal fees from Idorsia, grants submitted work; .	m Taked	a, during t	he conduct of the	e study; gr	ants and personal fees from Amicu	ıs,



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.